Tae-Jung Kim
Overview
Explore the profile of Tae-Jung Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
776
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Malapelle U, Chen C, de Alava E, Hofman P, Kazdal D, Kim T, et al.
J Pathol Clin Res
. 2025 Mar;
11(2):e70018.
PMID: 40052485
Current European/US guidelines recommend that molecular testing in advanced non-small cell lung cancer (aNSCLC) be performed using next-generation sequencing (NGS). However, the global uptake of NGS is limited, largely owing...
2.
Kim J, Kim M, Lim D, Lee H, Lee J, Kwon H, et al.
Endocrinol Metab (Seoul)
. 2025 Jan;
PMID: 39805576
Background: This study aimed to evaluate the applicability of deep learning technology to thyroid ultrasound images for classification of thyroid nodules. Methods: This retrospective analysis included ultrasound images of patients...
3.
Oh J, Lee J, Chung S, Lee Y, Kim T, Kim T, et al.
Tuberc Respir Dis (Seoul)
. 2025 Jan;
PMID: 39799978
Connective tissue disease (CTD) comprising a various range of autoimmune disorders is often accompanied by lung involvement, which can lead to life-threatening complications. The main types of CTDs that can...
4.
Kim T, Kim T, Han E, Min G, Park S, Park S, et al.
Cancer Med
. 2024 Dec;
14(1):e70565.
PMID: 39737815
Background: The prognostic significance of extranodal sites in stage IV diffuse large B-cell lymphoma (DLBCL) remains uncertain, making it challenging to select appropriate treatment strategies for individual patients. In this...
5.
Kim T, Kim T, Han E, Min G, Cho S, Jeon Y
Front Oncol
. 2024 Dec;
14:1461268.
PMID: 39717753
Introduction: Peripheral T-cell lymphomas (PTCLs) have poor outcomes in the relapsed/refractory (R/R) setting. In this study, we evaluated the efficacy of dexamethasone, L-asparaginase, ifosfamide, carboplatin, and etoposide (DL-ICE) chemotherapy followed...
6.
Chou T, Dacic S, Wistuba I, Beasley M, Berezowska S, Chang Y, et al.
J Thorac Oncol
. 2024 Nov;
20(3):311-330.
PMID: 39579981
Introduction: With the implementation of low-dose computed tomography screening, multiple pulmonary tumor nodules are diagnosed with increasing frequency and the selection of surgical treatments versus systemic therapies has become challenging...
7.
Lim J, Kang H, Moon M, Yeo C, Sa Y, Kim T, et al.
Transl Lung Cancer Res
. 2024 Aug;
13(7):1463-1480.
PMID: 39118882
Background: Recent evidences showed that resection of lung tumor post-targeted therapy has shown progression-free survival (PFS) benefits in initially unresectable patients. The aim of this study is to evaluate pathologic...
8.
Lee S, Lee E, Lim J, Ku B, Seong Y, Ryu J, et al.
Anal Chem
. 2024 Jun;
96(25):10246-10255.
PMID: 38858132
Hypoxia is a representative tumor characteristic associated with malignant progression in clinical patients. Engineered in vitro models have led to significant advances in cancer research, allowing for the investigation of...
9.
Lee S, Kim K, Lee E, Lee K, Ahn K, Park H, et al.
NPJ Precis Oncol
. 2024 May;
8(1):111.
PMID: 38773241
Patient-derived organoids (PDOs) are valuable in predicting response to cancer therapy. PDOs are ideal models for precision oncologists. However, their practical application in guiding timely clinical decisions remains challenging. This...
10.
Saito A, Terai H, Kim T, Emoto K, Kawano R, Nakamura K, et al.
Cancer Med
. 2024 Mar;
13(4):e7077.
PMID: 38457233
Background: Companion diagnostic tests play a crucial role in guiding treatment decisions for patients with non-small cell lung cancer (NSCLC). The Oncomine Dx Target Test (ODxTT) Multi-CDx System has emerged...